<?xml version="1.0" encoding="UTF-8"?>
<p id="Par61">In an open-label, nonrandomized clinical trial using 
 <italic>hydroxychloroquine</italic> and 
 <italic>azithromycin</italic> for COVID-19 treatment, all 6 patients receiving combination therapy exhibited virological cure. In comparison, only 57.1% of the patients treated with hydroxychloroquine as a single drug and 12.5% in the control group exhibited virological cure (
 <italic>P</italic> &lt; 0.001). Furthermore, one patient, who was treated with hydroxychloroquine as a single drug and still PCR-positive at day 6, received azithromycin, resulting in virological cure. The authors propose that hydroxychloroquine in combination with azithromycin treatment might be an efficient antiviral therapy for COVID-19 [
 <xref ref-type="bibr" rid="CR46">46</xref>].
</p>
